Erratum: FTY720/fingolimod decreases hepatic steatosis and expression of fatty acid synthase in diet-induced nonalcoholic fatty liver disease in mice (Journal of Lipid Research (2019) 60 (1311-1322) DOI: 10.1194/jlr.M093799)

Potential conflicts of interest were inadvertently omitted. Dr. Sanyal has served as a consultant to Astra Zeneca, Bristol Myers Squibb, Conatus, Allergan, Merck, Genentech, Birdrock, 89Bio, Poxel, Surrozen, Gilead, Boehringer-Ingelhiem, Siemens, Sanofi, Lipocine, Madrigal, Glympse, Ferring, Artham, Terns, Lilly, Novartis, Novo Nordisk, and Pfizer. He has served as an unpaid advisor to Exhalenz, Valeant, Intercept, Echosense, Immuron, Fortress Labs, Metacrine, Cirius, Galectin, Pliant, Fractyl, Northsea Pharma, Gencia, BiocellBio, Path AI, Affimune, Histoindex, Chemomab, Blade, Nordic Bioscience, and Zydus. His institution has received grant support from Gilead, Salix, Bristol Myers Squibb, Tobira, Shire, Intercept, Merck, Astra Zeneca, Mallinckrodt, Cumberland, and Novartis. Dr. Sanyal receives royalties from Elsevier and UptoDate. He is the President of Sanyal Biotechnology and has stock options in Genfit, Akarna, Tiziana, Indalo, Durect, and Inversago. VCU has ownership interests in Sanyal Biotechnology.